See other companies on Welcome to the Jungle
Synchron
Implantable brain computer interfaces
- 101-200 employees
- Healthcare
- B2B
- Manufacturing
- MedTech
- Bedford-Stuyvesant, NY
Jump to section
Company mission
To create an endovascular implant that can transfer information from every corner of the brain at scale.
Our take
Brain-machine interfaces have long been a technological dream, shouldering hope of bringing communication and movement to paralysed people. However, the need to drill into a patient’s skull in order to deliver these interfaces had held back advancements in the field for years.
Synchron, founded in 2016, is the first company to propose a safer delivery method via the jugular vein. Its proposition does not require heavily invasive surgery, and the interfaces may be used in a wide range of paralysis cases. The intended result is the ability to send texts and emails, and access online services such as health appointments and banking, all with the power of thought.
The company’s technology is currently being trialled after earning FDA approval in 2021, with its work backed by top research institutes in the field. Synchron has hopes that its final showpiece may be whole-brain data transfer, but for now its focus on giving communication to the millions of paralysis patients in the world represents a market opportunity in the tens of billions
Kirsty
Company Specialist at Welcome to the Jungle
Funding (last 2 of 6 rounds)
Dec 2022
$75m
SERIES C
Aug 2021
$10m
GRANT
Total funding: $134.3m
This company has top investors
Leadership
Thomas Oxley
(CEO)Interventional Neurologist with Mount Sinai Health System. Associate Professor at the University of Melbourne. Medical Director and Founder of Vasculab.